Atara Biotherapeutics Inc (ATRA) - Total Assets
Based on the latest financial reports, Atara Biotherapeutics Inc (ATRA) holds total assets worth $30.17 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore ATRA operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Atara Biotherapeutics Inc - Total Assets Trend (2012–2024)
This chart illustrates how Atara Biotherapeutics Inc's total assets have evolved over time, based on quarterly financial data. See Atara Biotherapeutics Inc shareholders equity for net asset value and shareholders' equity analysis.
Atara Biotherapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Atara Biotherapeutics Inc's total assets of $30.17 Million consist of 59.5% current assets and 40.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 22.9% |
| Accounts Receivable | $1.48 Million | 1.4% |
| Inventory | $10.65 Million | 9.8% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Atara Biotherapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ATRA company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Atara Biotherapeutics Inc's current assets represent 59.5% of total assets in 2024, a decrease from 98.9% in 2012.
- Cash Position: Cash and equivalents constituted 22.9% of total assets in 2024, down from 98.1% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is inventory at 9.8% of total assets.
Atara Biotherapeutics Inc Competitors by Total Assets
Key competitors of Atara Biotherapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Atara Biotherapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.02 | 0.59 | 6.31 |
| Quick Ratio | 1.02 | 0.50 | 6.31 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $375.00K | $-64.12 Million | $440.37 Million |
Atara Biotherapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Atara Biotherapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.97 |
| Latest Market Cap to Assets Ratio | 0.32 |
| Asset Growth Rate (YoY) | -34.1% |
| Total Assets | $109.10 Million |
| Market Capitalization | $35.19 Million USD |
Valuation Analysis
Below Book Valuation: The market values Atara Biotherapeutics Inc's assets below their book value (0.32x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Atara Biotherapeutics Inc's assets decreased by 34.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Atara Biotherapeutics Inc (2012–2024)
The table below shows the annual total assets of Atara Biotherapeutics Inc from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $109.10 Million | -34.08% |
| 2023-12-31 | $165.50 Million | -56.03% |
| 2022-12-31 | $376.42 Million | -19.59% |
| 2021-12-31 | $468.13 Million | -20.40% |
| 2020-12-31 | $588.12 Million | +71.49% |
| 2019-12-31 | $342.94 Million | -12.48% |
| 2018-12-31 | $391.84 Million | +79.93% |
| 2017-12-31 | $217.78 Million | -17.48% |
| 2016-12-31 | $263.91 Million | -18.79% |
| 2015-12-31 | $324.98 Million | +206.23% |
| 2014-12-31 | $106.12 Million | +104.76% |
| 2013-12-31 | $51.83 Million | +1108.11% |
| 2012-12-31 | $4.29 Million | -- |
About Atara Biotherapeutics Inc
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as… Read more